A novel speculum-free imaging strategy for visualization of the internal female lower reproductive system

Mercy N. Asiedu¹,²,³*, Júlia S. Agudogo¹,², Mary E. Dotson², Erica Skerrett¹,²,³, Marlee S. Krieger¹,², Christopher T. Lam¹,²,³, Doris Agyei⁴, Juliet Amewu⁴, Kwaku Asah-Opoku⁶,⁷, Megan Huchko³,⁵, John W. Schmitt³,⁵, Ali Samba⁶,⁷, Emmanuel Srofenyoh⁴ & Nirmala Ramanujam¹,²,³

Fear of the speculum and feelings of vulnerability during the gynecologic exams are two of the biggest barriers to cervical cancer screening for women. To address these barriers, we have developed a novel, low-cost tool called the Callascope to reimagine the gynecological exam, enabling clinician and self-imaging of the cervix without the need for a speculum. The Callascope contains a 2 megapixel camera and contrast agent spray mechanism housed within a form factor designed to eliminate the need for a speculum during contrast agent administration and image capture. Preliminary bench testing for comparison of the Callascope camera to a $20,000 high-end colposcope demonstrated that the Callascope camera meets visual requirements for cervical imaging. Bench testing of the spray mechanism demonstrates that the contrast agent delivery enables satisfactory administration and cervix coverage. Clinical studies performed at Duke University Medical Center, Durham, USA and in Greater Accra Regional Hospital, Accra, Ghana assessed (1) the Callascope's ability to visualize the cervix compared to the standard-of-care speculum exam, (2) the feasibility and willingness of women to use the Callascope for self-exams, and (3) the feasibility and willingness of clinicians and their patients to use the Callascope for clinician-based examinations. Cervix visualization was comparable between the Callascope and speculum (83% or 44/53 women vs. 100%) when performed by a clinician. Visualization was achieved in 95% (21/22) of women who used the Callascope for self-imaging. Post-exam surveys indicated that participants preferred the Callascope to a speculum-based exam. Our results indicate the Callascope is a viable option for clinician-based and self-exam speculum-free cervical imaging.

Clinical study registration: ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/record/NCT00900575, Pan African Clinical Trial Registry (PACTR) https://www.pactr.org/PACTR201905806116817.

For most women, transgender men, and gender non-conforming persons with a vagina and/or cervix, a gynecologic exam, also known as a pelvic exam, is a regular part of wellness visits starting at the age of 21 until age 65 or later. The internal examination aspect of the pelvic exam traditionally utilizes a metal or plastic duckbill speculum to separate the vaginal canal so a clinician can view the cervix. The speculum-based pelvic exam is performed for various reasons including: (1) cervical cancer screening, i.e. visualizing the cervix and vaginal walls for any malignancy or suspicious pre-cancerous or cancerous lesions and obtaining cell and tissue samples to detect cancerous cells¹, (2) checking for sexually transmitted diseases, vaginal infections, and abnormal discharge in symptomatic patients², (3) checking cervical dilation during pregnancy³, (4) placement and removal of...
intrauterine device (IUD) as well as monitoring strings for placement verification14, and (5) collecting evidence of sexual abuse15. While speculum-based exams are one of the most important aspects of reproductive healthcare, it is a large cause of fear of the exam6–9.

In the United States, middle-aged African-American women have the highest rates of cervical cancer incidence and mortality at more than double that of their white counterparts18,19. This disparity in cancer incidence and mortality can be partially attributed to a sixfold increase in non-adherence to screening relative to the general population, largely because of the perceived pain of the screening procedure among African American women and the cost of office visits8. The supine position a patient is required to be in for the exam, and the form factor of the speculum itself, creates anxiety, fear, discomfort, pain, embarrassment, and vulnerability, which are significant reasons why patients avoid gynecological exams, including the specific speculum-based exams, such as the Pap smear and colposcopy used to screen for cervical cancer6–9. One longitudinal study of sexually active young women indicated that women's perceptions of pain for the speculum during an exam led directly to poor compliance with follow-up procedures after the Pap smear10. In Ghana, cervical cancer is the most common cancer in women. The high prevalence has been attributed to inadequate awareness of the disease, limited access to care, fear, and cultural taboos surrounding the exam and reproductive health more broadly12–15. These barriers to screening in the United States and Ghana are echoed globally; for example, a study of Australian women's attitudes towards physician-insertion versus self-insertion of a speculum found that 91% of women (n = 133) preferred self-insertion, and that having another person insert the device caused discomfort, embarrassment, and vulnerability16. Further, a study of women in Moshi, Tanzania (n = 354) showed that key barriers to obtaining gynecological exams included concerns about embarrassment and pain due to the speculum, and physician gender17. Discomfort from the speculum is particularly exacerbated in patients with vaginismus, a condition involving involuntary tightening of the vagina often caused by sexual abuse18,19. Additionally, countries with high sexual violence rates tend to have high rates of cervical cancer incidence and mortality20–22.

A second significant challenge in gynecology is providing adequate care to female-to-male (FTM) transgender persons. Over 90% of FTM transgender persons retain their cervices after transitioning and still require comprehensive gynecologic care, including cervical cancer screening23. Various studies have shown that FTM persons are less likely to obtain gynecologic care and cite emotional and psychological distress, negative health-care experiences, mistreatment at health facilities and refusal of services based on their gender identity24–28. This is especially problematic given that FTM persons are at a higher risk for undetected HPV infection and subsequent cervical cancer23. This is exacerbated in countries where transgender persons face criminalization and are marginalized29. Surveys of obstetricians-gynecologists found that only about 30% of respondents felt comfortable caring for FTM patients30. Overall, very little information is available to help clinicians improve the gynecologic exam and increase health seeking behaviors for FTM transgender persons.

A third barrier to gynecologic exams stem from travel and time factors associated with visiting a health center28,30. Most women have to take time away from work, childcare, housework, and family or business duties in order to go to clinics for screening21. Additionally, in certain regions cervical cancer screening clinics can only be found in tertiary institutions, which require significant travel times and higher associated costs, particularly for women in rural areas31. Individuals in rural communities often have to travel far distances through unreliable public transportation to reach a health facility. Even if women in rural communities do have access, many health facilities in low-resource areas of the United States and other regions of the world do not have the tools to perform well-established gynecological exams20,32,33,34. In high-income areas where institutions exists with the resources to screen for cervical cancer, factors such as work and busy life schedules still deter women from getting screened. A study in Sweden seeking to understand barriers to clinic-based cervical cancer examinations found that more than half of non-compliant study participants stated difficulties in taking time off from work29.

Creating low-cost yet high-quality medical tools to increase access to lifesaving healthcare assessments such as the gynecological exam could potentially reduce attrition rates for preventive screening and diagnostic tests, particularly among marginalized persons with cervices and/or vaginas33.

Another significant, albeit less talked about barrier to seeking gynecological exams, is a lack of knowledge of the reproductive anatomy and reproductive health, which can deter positive health-seeking behavior36. In 2014, the American Congress of Obstetricians and Gynecologists (ACOG) and Women's Health magazine conducted a survey of 7,500 women and found that 64% could not identify a picture of the cervix. The same survey found that 54% of women kept secrets from their gynecologists related to their reproductive anatomy and health37. A study of FTM transgender persons found that they had little knowledge of their reproductive health generally, as well as very little information regarding their very unique and specific reproductive health needs and experiences38. Educating people about their reproductive health and anatomy has been shown to increase positive health-seeking behaviour38–41. One strategy to empower women, FTM transgender persons, and non-binary persons with cervices to care and advocate for their reproductive autonomy is to provide self-imaging tools that allows them to visualize, understand, and appreciate their own vaginas and/or cervices.

Although studies have indicated that the speculum causes discomfort, the speculum has not been significantly redesigned in over 150 years despite rapid medical technology advancement. Obviating the need for a speculum by replacing it with a tool that enables increased comfort and the opportunity for self-exams without compromising efficacy, would not only make the traditional gynecological exam less intimidating and painful, but would also provide all individuals, including FTM persons, autonomy over their own pelvic exam, potentially empowering them to seek timely screening. This manuscript describes the potential for a novel technology called the Callascope to address the aforementioned barriers. The aims of this study are to: (1) demonstrate through bench testing methods that the Callascope image quality and application of liquid cervical cancer screening contrast agents is sufficient for cervical imaging and cervical cancer screening; (2) show that the Callascope enables speculum-free, clinician-imaging of the cervix with reduced patient discomfort and increased patient acceptance; (3) assess the feasibility of using the Callascope for speculum-free, self-cervix imaging by healthy volunteers,
with low discomfort and high ease-of-use; and (4) validate that results are consistent across multinational clinical settings. Our previous work describes the design exploration and prototyping of the Callascope introducer. We have also published studies of the development and testing of a low-cost tool, the Pocket Colposcope, for cervix imaging. However, this work is the first to describe a combined imaging and introducer system for speculum-free cervical imaging with contrast application. Additionally, this is the first clinical study that describes the use of such a device for both clinician-based and self-based cervix imaging in a multi-national setting.

Materials and methods
Description of the Callascope. Previous efforts to replace the speculum have replicated its function in a variety of ways including the use of plastic material for the body instead of metal, the use of an inflatable cuff to expand the vaginal walls and introducing a bolus of air to provide a line of sight to the cervix. These solutions function on the premise that the cervix and vaginal walls are viewed from outside the body either with the naked eye or a colposcope, and thus require expansion of the entire vaginal canal, which leads to discomfort. Furthermore, none of these devices have been effective in removing the barriers to screening described above. The Callascope addresses both issues by fundamentally shifting the way the exam is performed with two separate components—a Calla Lily shaped introducer and a slender tampon-shaped camera that fits seamlessly within the introducer.

Callascope camera. The custom-built camera has a slim tubular body (~9 mm diameter, ~120 mm length) to fit within the Callascope introducer (described below) and is designed to have a 2–5 Megapixel (MP) CMOS sensor with a lens and a concentric ring of white LEDs at its tip (Fig. 1a,b). The front end of the camera is sealed with a lens and a hydrophobic window, secured with medical-grade epoxy that enables the camera to be water-resistant, and prevents fogging from the humidity of the vaginal cavity. There is a handle at the distal end, which enables brightness adjustment and image capture (Fig. 1a,b). The camera connects via USB to a mobile phone, tablet or laptop. The USB port connection powers the Callascope camera and LEDs; therefore, the device does not require a separate battery or electrical plug-in. Patient data and images are automatically uploaded to a HIPAA compliant cloud-based server, via Amazon Web Services, and are accessible through a web portal. The Callascope allows the user to visualize the vaginal walls as well as the cervix on a portable device. The data collected through the online platform includes information about the person collecting the data, as well as the date and time of collection. The current version of the software also allows an approved remote clinician to log in to review images and make a diagnosis, thus enabling telemedicine. Alternatively, we are exploring methods for these images to be processed using an artificial intelligence algorithm, for risk assessment and to reduce the need for experts.

Callascope introducer. The current gynecological exam uses the duckbill speculum to part the vaginal walls to allow for viewing of the cervix from outside the body. In contrast, the slim tubular body of the Callascope and the Calla Lily shaped tip of the introducer can be inserted into the vagina, providing a narrow channel through which a camera is inserted to internally capture a video and/or image of the vaginal walls and cervix (Fig. 1c). The video and/or images are seen in real-time on an external screen such as a cell phone, tablet or laptop computer. In order to provide adequate visualization of the cervix and vaginal canal for diagnosis, the device positions the cervix so that the opening to the uterus (i.e., the os) is centered in the image. The Calla Lily shaped tip is the key innovation that allows for speculum-free visualization of the cervix, which typically sits in a tilted position. Once inserted, the asymmetric tip is rotated until the extended lip tilts the cervix into view. In addition to the opening that allows for the camera to be inserted, the introducer has a small working channel along the walls, which can be used for contrast agent application and sample collection during cervical cancer screening procedures (Fig. 1c,d). The distal end (the part farthest from the cervix) of the contrast channel has a Luer lock connector, which couples to a Luer lock syringe for contrast application. The proximal end (the part closer to the cervix) has a nozzle, which sprays the contrast agent uniformly over the surface of the cervix. The nozzle has several holes designed with varying angles to cover a cervix with diameter of 25–30 mm when the camera positioned at a distance of 25–30 mm away from the cervix. Finally, the internal lining of the Calla Lily shaped tip has a reflective coating to ensure uniform illumination and coloration across the entire field of view for imaging. Figure 1e,f demonstrates the insertion of the standard duckbill speculum into the vaginal canal and expansion to bring the cervix into view by an external imaging source. In the clinical studies described in subsequent sections, the Callascope camera (without the introducer) was used to capture the field of view of the cervix, enabled by the speculum. Note that the introducer and camera are separable and the camera can be utilized without the introducer. Figure 1g,h demonstrates insertion of the Callascope (both the camera and introducer) into the vaginal canal and manipulation of the tilted cervix with the curved tip to center the cervix in the field of view. Figure 1i shows a schematic of optimal cervix visualization with all four quadrants and the cervical os in view.

Callascope image quality and contrast application testing. The resolution, Weber’s contrast and field of view testing as described by Lam et al., 2018 was performed on the Callascope camera and compared to a standard $20,000 standard-of-care colposcope (Leisegang Optik 2)⁶⁷. To test the resolution, both devices were used to image a USAF 1951 resolution target. Resulting images were analyzed using a line scan method with open source Fiji software. The group and element of the smallest resolvable parallel lines on the resolution target were determined and used to obtain the smallest resolvable feature size from the USAF 1951 resolution target interpretation table. To determine Weber’s contrast, the pixel intensity values of the mock cervix lesion region in white (I_max) and non-lesion background cervix region in reddish pink (I_min) were determined using the open source Fiji software and used to calculate the contrast with the equation I_max − I_min. The field of view was processed using an artificial intelligence algorithm, for risk assessment and to reduce the need for experts. | Copyright and Disclaimer © The Author(s) 2020. Published by Springer Nature Limited.
Figure 1. The design of the Callascope promotes visualization of the cervix for diagnostic image capture without the speculum. (a) Detailed schematic of Callascope camera. Th: thickness, I.D: inner diameter, O.D: outer diameter. The camera module has a 2MP CMOS sensor, a lens, white illumination LED ring, and a micro processing board. A circular 5 mm hydrophobic window (Edmund optics) is placed over the camera lens and a concentric LED window is placed over the LEDs. A thin layer of black epoxy is applied between the outer edge of the hydrophobic window and the inner edge of the LED window to prevent LED illumination from causing a vignette in the image. The camera module is wired to a micro processing board that controls the LED brightness and connects the camera to a USB board. A female-to-male USB adapter is used to connect the USB board to a computer. A USB adaptor can be attached to enable connection to a phone or a tablet. (b) CAD model of the Callascope camera. (c) CAD model of the Callascope camera inserted into the introducer. (d) Close-up of the spray nozzle of the Callascope showing the fluid distribution path over a cervix. (e-i) Schematics of cervix visualization used in clinical studies. (e) The speculum inserted in closed position into a vagina with a tilted uterus. (f) Speculum bills expanded and used to center the cervix for the exam. The Callascope camera, without the introducer was inserted through the speculum to obtain an image with the cervix view enabled by the speculum. (g) The Callascope camera and introducer inserted into a vagina with a tilted uterus for cervix imaging without the speculum. (h) The Callascope introducer lip centering the cervix to enable imaging with the Callascope camera. (i) Schematic of a cervix showing the cervix quadrants and os (central red oval) that need to be viewed during cervix examination.
view was estimated by placing the camera a fixed distance from target objects of different size and determining the largest object that could be fully visualized by the camera. The colposcope and Callascope distances were set to be similar to the working distance used during a cervical exam. The Callascope field of view was 35 mm, whereas the field of view for the standard-of-care colposcope was at 300 mm at 7.5× magnification which is typically used to obtain a full, magnified field of view of the cervix.

To test the contrast application, a printed circular grid 30 mm in diameter (average cervix diameter), was placed over the cervix area 3D printed uterus model, with plastic tubing representing the vaginal canal. The liquid contrast was drawn with a Luer-lock syringe and attached to the Luer-lock connector on the contrast application channel of the introducer. The camera was inserted into the introducer and the introducer lip was placed up against the circular grid. The syringe was then compressed, enabling the liquid to flow through the channel on the introducer and spray out over the grid. Lugol’s iodine, was used to enable staining for visual assessment of coverage. The percentage of surface area stained was calculated. Testing of the contrast application over the grid of a cervix phantom was carried out for 4 application scenarios: 3 ml of contrast agent with a 3 ml syringe, and 3 ml, 2 ml and 1 ml of contrast agent (Lugol’s iodine which is for visualization of cervical disease) with a 10 ml syringe. 3 ml was selected as the maximum amount of liquid to prevent excess pooling, which would obstruct the view of the cervix for imaging. Each was repeated n = 5 times and averaged.

Clinical investigations in the U.S. and Ghana. Overview. This study consisted of two different arms to test feasibility of the Callascope for clinician- and self-imaging of the cervix. Arm 1 recruited patients who were receiving a routine Pap smear or visual exam of the cervix. Clinician-imaging of the cervix was performed using the speculum, and the Callascope introducer for vaginal expansion and cervix manipulation. Arm 2 recruited healthy volunteers in a clinical setting. Volunteers were provided with a Callascope and instructions to perform self-imaging of the cervix. We utilized a mixed methods approach where cervix images were collected with the Callascope, quantitative scores were collected with surveys, and voluntary qualitative feedback was collected via the comments section of the surveys or via audio.

Study settings. Both study arms were performed in tertiary health institutions in two different locations: (1) The Reproductive Health Unit at the Greater Accra Regional Hospital (GARH) in Accra, Ghana and (2) the Gynecology Clinic at Duke University Medical Center (DUMC) in Durham, USA.

Participants’ eligibility. 18 years or older, female, healthy volunteers accepted.

Inclusion criteria. Undergoing Pap smear, visual exam of the cervix or colposcopy.

Exclusion criteria. Women under the age of 18 (minors), recent episode of bleeding or preterm labor, pregnant women in their 2nd or 3rd trimesters, subjects who were not competent to give consent.

Sample size. Ghana (GARH: arm 1 n = 25, arm 2 n = 10 ) and the U.S. (DUMC: arm 1 n = 28, arm 2 n = 12 ). Clinicians (GARH: n = 2, DUMC: n = 1).

Disinfection safety procedures. Disinfection of the Callascope prior to use was performed by submersion in 2% hydrogen peroxide for 8 min at room temperature, as recommended for semi-critical devices (which contact mucous membranes or non-intact skin during use)\textsuperscript{50,51}. The Callascope camera (which is water-resistant) was also disinfected prior to each use with the same method. The Callascope introducers, which directly contact vaginal mucosa, were discarded after each patient use. A summary of data collected in the two study arms is shown in Table 1.

| Study | Method | Data collected |
|-------|--------|----------------|
| Study 1: Clinician-imaging of the cervix | Pair of cervix images, one using only a Callascope, the other using the Callascope camera through a speculum | Cervix images |
| | Patient pre-exam survey | Demographics; top features considered for screening (e.g. comfort, cost); initial perception of the speculum, Callascope, and self-screening |
| | Patient post-exam survey | Pain rating; comparison of speculum and Callascope, qualitative feedback/comments |
| Study 2: Self-imaging of the cervix | Self-imaging using a Callascope | Cervix images |
| | Clinician confirmation of cervix visualization during self-imaging | Successful / unsuccessful cervix visualization |
| | Volunteer pre-insertion survey | Demographics; top features considered for screening; perceptions of the speculum, Callascope, and self-screening |
| | Volunteer post-insertion survey | Ease of use and comfort level, qualitative feedback/comments |

Table 1. Summary of mixed data collected from the international clinical investigations in the U.S. and Ghana.
Ethics approval. The study was approved by the DUMC Institutional Review Board (Pro00008173, NCT00900575), by the Ghana Health Service Ethical Review Committee, and by the Ghana Food and Drugs Association Clinical Trials Department (PACTR201905806116817). All methods were performed in accordance with the relevant guidelines and regulations. All participants provided written informed consent prior to participation.

Comparison of the field of view and comfort between a clinician implemented speculum-free and speculum-based cervical visualization in patients in two international settings. This investigation was performed in health institutions in Ghana (GARH: n = 25) and the U.S. (DUMC: n = 28). Clinicians (GARH: n = 2, DUMC: n = 1) underwent a 30-min training on the use of the Callascope, which entailed an explanation of the Callascope functionality, the different parts of the Callascope (introducer and camera) and how they connect. Clinicians in the GARH study consisted of 2 reproductive health nurses with over 20 years of cervical cancer screening experience, whereas the clinician in the DUMC study consisted of a Gynecologist with over 30 years of cervical cancer screening experience. The training included a demonstration of a pelvic exam on a cervical exam and Pap smear test trainer (Nasco Life/Form). Clinicians were then asked to assemble the Callascope for use, and complete a pelvic exam with the Callascope on the test trainer to ensure that they could operate the device and visualize the cervix. Post-training, adult female patients undergoing routine Pap smears (DUMC and GARH) or visual inspection of the cervix with the naked eye (GARH only) were recruited by the clinicians. Patients who agreed to participate in the study completed a pre-exam survey to record demographic information as well as document their perceptions of the speculum, Callascope, and clinician vs. self-screening. All study participants received both the control (standard-of-care speculum exam with the Callascope camera) and the investigational device (the Callascope introducer with the camera inserted in it). Study participants received the control first, followed by the Callascope. This order was used to prevent any reduction in quality of samples obtained as part of standard clinical procedures in which cell samples are obtained. The study was designed with a two-minute delay between insertions. Since standard-of-care colposcopy imaging was not performed during the Pap smear (U.S.) or during visual inspection with acetic acid (VIA) using the naked eye, the Callascope camera, served as the colposcope, and was used in both arms to image the field-of-view afforded by the speculum and the Callascope introducer (the camera was inserted through the introducer in the test arm and through the speculum in the control arm). Participants completed a post-exam survey to assess comfort using a modified version of the 0–10 Universal Pain Assessment Tool, which shows a series of faces ranging from a happy face at 0, or “no pain”, to a crying face at 10, which represents “worst pain possible”.52 Using the faces and/or the written descriptions the participants selected the face which represented their level of pain during use of the Callascope and speculum. The participants’ overall perception of the Callascope and the speculum exam was acquired using a Likert scale. Image scores of the cervix were calculated by assigning 1 point for visualization of the cervical Os and 1 point for each of the 4 quadrants of the cervix visualized. The percentage of patients who had at least 2, 3, and 4 quadrants imaged, were compared for the Callascope introducer and speculum. The percentage of patients for whom the Os was visualized was also compared between the Callascope introducer and the speculum.

We tested feasibility of clinician-based imaging with contrast application using the Callascope camera and introducer with a subset of healthy volunteers (n = 5) as part of the DUMC study. Study participants had Lugol’s Iodine applied through the Callascope introducer contrast channel to observe contrast coverage. Despite observed adequate cervix coverage by the contrast, the study was discontinued due to excess pooling, even with 1 ml of liquid. Future studies are exploring methods to increase efficient spray coverage.

Testing the efficacy of self-examination in female volunteers. For the self-exam, volunteers (with no prior cervical cancer diagnosis) were trained to use the Callascope without a speculum, and to assess ease-of-use and the feasibility of self-imaging without clinician assistance. Volunteers (DUMC: n = 12, GARH: n = 10) were recruited using online and paper fliers, and by word of mouth. Participants completed a pre-insertion survey. At DUMC, participants were given a user kit containing a Callascope, Android phone and charger. Sani wipes, vaginal wipes, lubricating jelly, and a printed user guide. Participants were asked to watch a video tutorial on a custom-built mobile application, which provided information on how to assemble the Callascope and how to use it to capture images of the cervix. Participants then captured an image of their cervix with the Callascope in a private room, which took approximately 5–10 min. Participants inserted the device in a position that they preferred, though we recommended a semi-recumbent or a standing position with one leg raised. We observed that for most women, a semi-recumbent position was preferred. A few women mentioned using the standing position with one leg raised and placed on a ledge, similar to tampon insertion methods. A nurse confirmed whether the images captured were those of the cervix. In the GARH study, due to limited clinic time, participants did not watch the video tutorial, but instead were given the Callascope pre-assembled and connected to a phone. Participants were asked to image their cervix with a nurse present to confirm whether the image was indeed the cervix, a process which took approximately 5 min. After the self-exam, participants were asked to indicate their level of discomfort on a Likert scale with the following options: “No discomfort”, “Slight discomfort”, “Moderate discomfort”, “A lot of discomfort”, and “Extreme discomfort”. They were also asked to indicate how easy or difficult it was to follow the instructions and to use the Callascope to find and manipulate their cervix. The number of women who were able to attain an image of their cervix, as confirmed by the study nurse was recorded.

Statistical analysis. Pre-exam Likert scale responses on willingness, as indicated in Table 2, were analyzed using a non-parametric Wilcoxon signed-rank test (one-tailed, paired, alpha = 0.025). A non-parametric Wilcoxon signed-rank test was used to analyze the post-exam survey data comparing the discomfort level
between the speculum and the Callascope (one tailed, paired, alpha = 0.025). A non-parametric Mann–Whitney rank test was used to compare discomfort level between the study sites for both devices (two-tailed, unpaired, alpha = 0.05). Power calculations, using PASS 2015 power program, indicated that a paired, two-sided t-test achieves 80% power to detect an effect size is 0.572 (Cohen's d) for n = 50 subjects, an effect size of 0.7 for n = 36 subjects and an effect size of 0.8 for n = 28 respectively, at 0.05 level of significance. Since the self-exam was exploratory, no power analysis and statistical tests were performed within each site. Likert scale responses of participant discomfort and ease-of-use were analyzed qualitatively within study sites. Statistical comparison of

### Table 2. Participant demographics and survey responses. Likert scale responses are grouped into two.

| Value/options                          | Clinician-imaging (n = 53) | Self-imaging (n = 22) |
|---------------------------------------|-----------------------------|-----------------------|
| **Race (pre-survey)**                 |                             |                       |
| Asian                                 | 0 (0%)                      | 1 (4%)                |
| Black                                 | 25 (100%)                   | 13 (46%)              |
| Hispanic (white)                      | 0 (0%)                      | 1 (4%)                |
| Hispanic (other)                      | 0 (0%)                      | 3 (11%)               |
| Non-Hispanic White                    | 0 (0%)                      | 8 (29%)               |
| Unknown                               | 0 (0%)                      | 1 (4%)                |
| Unanswered                            | 0 (0%)                      | 1 (4%)                |
| **Age (years) (pre-survey)**          |                             |                       |
| Median                                | 40–44                       | 31                    |
| Range                                 | 21–59                       | 25–65                 |
| **BMI (pre-survey)**                  |                             |                       |
| Median                                | 30.1                        | 30.3                  |
| Range                                 | 21–49                       | 16–58                 |
| **Number of vaginal births**          |                             |                       |
| 0                                     | 12 (48%)                    | 8 (29%)               |
| 1–2                                   | 5 (20%)                     | 12 (43%)              |
| 3–5                                   | 8 (32%)                     | 6 (21%)               |
| Unanswered                            | 0 (0%)                      | 1 (4%)                |
| **Regular use of tampon or menstrual cup** |                             |                       |
| Yes                                   | 2 (8%)                      | 10 (36%)              |
| No                                    | 23 (92%)                    | 15 (54%)              |
| Unanswered                            | 0 (0%)                      | 3 (11%)               |
| **Number of prior speculum exams**    |                             |                       |
| ≤ 5                                   | 25 (100%)                   | 4 (14%)               |
| > 5                                   | 0 (0%)                      | 19 (68%)              |
| Unanswered                            | 0 (0%)                      | 5 (18%)               |
| **Perception of speculum as a barrier** |                           |                       |
| No-small barrier                      | 23 (92%)                    | 17 (61%)              |
| Med-large barrier                     | 2 (8%)                      | 9 (32%)               |
| Unanswered                            | 0 (0%)                      | 2 (7%)                |
| **Willingness level to use speculum/Callascope based on appearance** |                 |                       |
| Not–slightly                          | 14 (56%)                    | 12 (43%)              |
| Very–extremely                        | 11 (44%)                    | 24 (96%)              |
| Unanswered                            | 0 (0%)                      | 0 (0%)                |
| p-value                               | 3e–4                        | 1e–2                  |
| **Willingness level to have a physician use a speculum/Callascope** |                       |                       |
| Not–slightly                          | 11 (44%)                    | 5 (20%)               |
| Very–extremely                        | 14 (56%)                    | 20 (80%)              |
| Unanswered                            | 0 (0%)                      | 1 (4%)                |
| p-value                               | ns                          | 2e–2                  |
| **Willingness level to perform a self-exam with a speculum/Callascope** |                       |                       |
| Not–slightly                          | 18 (72%)                    | 9 (36%)               |
| Very–extremely                        | 7 (28%)                     | 16 (64%)              |
| Unanswered                            | 0 (0%)                      | 0 (0%)                |
| p-value                               | 2e–3                        | 3e–3                  |

Not asked
Bench testing demonstrates that the Callascope enables sufficient image quality and contrast application for colposcopy, without the need for a speculum. To demonstrate that the Callascope performs equivalently to the standard-of-care clinical colposcope, images of a USAF 1951 resolution target and a mock cervix were obtained using the Callascope (at 4× magnification, at 30 mm working distance), and a standard-of-care colposcope, Leisegang Optik 2 (at 3.75× magnification), as seen in Fig. 3a. The smallest resolvable feature size for the standard-of-care Leisegang colposcope was 50.6 μm, whereas the Callascope camera’s was 99.2 μm. Both devices enable visualizing cervical lesion features, which tends to be greater than 1 mm (1,000 μm). Weber’s contrast was slightly higher for the standard-of-care Leisegang colposcope than the Callascope camera (2.13 vs. 1.44), however, this corresponds to minimal degradation in contrast as is evident from the mock cervix images. The field of view at respective magnification/working distance was 50.6 mm for the standard-of-care Leisegang and 30 mm for the Callascope camera. The cervix diameter typically ranges from approximately 25 mm to 30 mm and thus is within the field of view achieved by either device. A disadvantage of the standard-of-care colposcope is that it is located outside the body, typically at a distance of about 30 cm (300 mm) from the cervix, capturing images including extraneous information like the speculum and vaginal walls.

Testing of the contrast applicator over the grid of a cervix phantom was carried out for 4 application scenarios: 3 ml of contrast agent with a 3 ml syringe, and 3 ml, 2 ml and 1 ml of contrast agent (Lugol’s iodine, which is for visualization of cervical disease) with a 10 ml syringe (Fig. 3b). Administration of 3 ml and 2 ml volume of the contrast agent with the 10 ml syringe provided the most uniform and complete distribution over the grid (Fig. 3c). This is likely due to the higher pressure afforded by the 10 ml syringe. Further, comparable distribution was observed applying the contrast agent Lugol’s iodine, in vivo, through the Callascope channel, for n = 5 healthy volunteers. (Fig. 3d).

Participants demographics and baseline perceptions of the Callascope vs. the speculum—a two country assessment. After confirming comparable image quality between the Callascope and a standard-of-care colposcope, a two-arm clinical study was performed to assess clinical cervix images capture by a clinician using the Callascope camera with a speculum and with the Callascope introducer, as well as to assess the feasibility of performing a self-exam using the Callascope. This study consisted of two groups of participants: (1) patients undergoing a routine Pap smear or visual exam of the cervix, who then underwent a clinician-based exam where the Callascope camera was used to image the cervix either through the Callascope introducer or through a speculum (to mimic conventional speculum-based visualization); and (2) volunteers in a clinical setting who performed self-imaging of the cervix using the Callascope camera and introducer. Both study arms were performed in tertiary healthcare institutions in two different locations: Greater Accra Regional
Hospital (GARH) in Accra, Ghana and Duke University Medical Center (DUMC) in Durham, USA. Participant demographics for clinician-imaging and self-imaging from both DUMC and GARH clinical sites are summarized in Table 2. Additionally, Table 2 includes patient’s baseline perceptions of the Callascope compared to the speculum for gynecological examination. These results were derived from a pre-examination questionnaire. Factors that are known to impede visualization of the cervix, such as high BMI, high number of vaginal births, and age-related vaginal atrophy, were documented in the questionnaire. The median age across sites and studies was within the established age for cervical cancer screening (21–65) and the participants were representative of the population. Median BMI for participants in the clinician-imaging cohort at both DUMC and GARH was ~ 30. For the self-imaging arm of the study, the median BMI at GARH fell within the overweight range, whereas at DUMC it fell within the normal weight range. We enrolled women across a representative range of parities in the clinician-imaging cohort, unintentionally however, most women in the self-imaging cohort had a parity of zero. Most women in the DUMC study had previously undergone more than five speculum-based exams, whereas most women in the GARH study had undergone less than five speculum-based exams. Additionally, we collected information on regular use of tampons/menstrual cups. None of the participants from GARH used tampons or menstrual cups, whereas about 50% of women from DUMC regularly used tampons and/or menstrual cups.

Before participants were shown the Callascope device, most women did not consider the speculum a barrier to being screened for cervical cancer, as most participants indicated they felt there was no other alternative and
it was necessary for screening. After being shown the Callascope, participants overwhelmingly preferred the appearance and ergonomics of the Callascope to that of the duckbill speculum. Most women across both study sites reported being very or extremely willing to use the Callascope and not willing or only slightly willing to use the speculum for both clinician-imaging and self-imaging of the cervix.

Clinician imaging with the Callascope provides comparable field of view and superior comfort compared to clinician imaging with a conventional duckbill speculum. Cervix images captured using the Callascope either through the introducer or speculum are shown in Fig. 4a. The overall patient perceptions of the Callascope compared to the speculum after use are shown in Fig. 4b. These figures demonstrate overall higher preference for the Callascope among both patients in DUMC (~ 85%) and GARH (~ 75%). These results were derived from a post-examination questionnaire where participants were asked to reflect on the overall exam, including ease of finding the cervix, discomfort/comfort and image visualization. There was no correlation between regular tampon/menstrual cup use and participants’ response. In addition, patients scored the pain associated with the Callascope and duckbill speculum using a Universal Pain Assessment Tool52. Patients provided pain scores for insertion and manipulation of each device to view the cervix, as well as for removal of the device. The Callascope caused significantly less pain than the speculum in both the DUMC and GARH cohorts (Fig. 4c,d).

We also analyzed visualization of the cervix with each device. The cervix is approximately a circular organ, and visualization of cervical lesions are typically marked on pre-determined quadrants of the cervix (Fig. 1i). The number of cervix quadrants visualized by the speculum and Callascope introducer is shown in Fig. 5. The percentage of patients for whom cervical os was visualized for the Callascope and speculum. P-values: * ≤ 0.05, ** ≤ 0.005, *** ≤ 0.0005, **** ≤ 0.00005. Error bars indicate standard deviation. Grey bars represent speculum results and black bars represent Callascope introducer results.
in Fig. 4e,f, respectively. The percentage of patients in whom the cervical os was visualized is also shown in Fig. 4g. Mean visual scores of cervigrams were calculated by assigning 1 point for visualization of the cervical os and 1 point for each of the 4 quadrants of the cervix visualized and averaging these points. The mean scores of cervigrams captured at DUMC were 4.82/5 for the speculum and 3.89/5 for the Callascope; the mean scores of images captured at GARH were 4.95/5 for the speculum and 3.67/5 for the Callascope. The differences in these mean values are not statistically significant. Even though the speculum is the gold-standard, scores of less than 5 for the speculum were due to the cervix being obscured by the vaginal wall between the bills of the speculum. The Callascope does not have bills that push on the vaginal walls, but rather provides a 360-degree expansion of vaginal walls with the asymmetrical curved tip of the introducer. The Callascope enabled visualization of the os in 78.6% of DUMC and 80% of GARH participants. Whereas, the speculum enabled visualization of the os in 96% of DUMC and 100% of GARH. The Callascope enabled visualization of at least 2 cervix quadrants in 89% of DUMC and 84% of GARH participants, at least 3 quadrants in 72% of GARH and 71% of DUMC, and all 4 quadrants in 50% of DUMC and 44% of GARH.

On average clinicians found the Callascope better than the duckbill speculum for manipulating the cervix into an acceptable place for visualization. Two out of three clinicians found the Callascope to be the same or better than the speculum for cervix visualization in their patients (n = 25 patients). One clinician found it to be the same or better than the speculum for 65% of 28 patients and worse than the speculum for 35% of 28 patients.

**Study participants are able to perform self-exams to visualize their own cervices.** Cervix images captured through self-examination are shown in Fig. 5a. A representative video shows how the Callascope is inserted and manipulated by a participant to visualize her cervix as shown in the link included here (https://drive.google.com/open?id=1oA7d1512nhtsQYMDSWVU-RdY1Tvysp). Eleven of 12 participants at DUMC and all 10 participants at GARH were able to visualize their cervix by self-imaging. In a post-insertion survey (Fig. 5b,c), no participant indicated extreme discomfort, and 70% of DUMC and 90% of GARH participants indicated no or slight discomfort. Most participants at DUMC (~60%) and GARH (~70%) found the Callascope easy to insert and use to find and image their cervices. Only one DUMC participant reported on the survey that it was extremely hard to use. We included women and clinicians from both a high-income and a lower-middle income country (US and Ghana) and found no significant differences in outcomes. The results from the self-imaging study agree with those from an earlier feasibility study conducted with an earlier version of the Calla Lily introducer where over 90% of participants in the earlier feasibility study preferred the Callascope to the speculum, and 83% were able to visualize their cervix. There was no correlation between regular tampon/menstrual cup use and participants response. Post-study, participants provided optional written/audio comments, with representative comments in the paragraphs below.

“The pictures were, well, sort of fascinating to see yourself the way a Doctor or a medical student sees other people’s bodies. Some Other feeling you know? Some feeling of alienation in looking at myself in terms of such a physical view that is so different than self-image. Yet also it’s just nice to be able to really access your own body visually… It probably left me more motivated to undergo gynecological exams if recommended.” – Self-exam study participant.

“I’m a cis female in my late twenties with an IUD, so I’ve had several gynecological exams over the years and I have been on the receiving end of a speculum and so I guess I was expecting this to be a similar experience, very clinical and impersonal in a way. I think when I think of female reproductive anatomy I think of that it’s enigmatic, that it’s hidden from us physically. We don’t have a lot of external genitalia, but it’s also kind of hidden in the way that we don’t talk much about vaginas and uteruses and cervices. So, this was kind of an eye-opening experience to be able to visualize something that is so intrinsically a part of me that I have never seen in this way before. It was much more personal and fascinating than I expected it to be.” – Self-exam study participant.

**Discussion**

The Callascope has the potential to offer an alternative to the standard duckbill speculum for clinical exams, which like the self-breast exam, will allow individuals with cervices to perform basic cervical exams in their own homes. Since it enables visualization of the cervix, the Callascope can potentially also be used by individuals at home for self-imaging to detect cervical cancer, infections, locating intrauterine device (IUD) strings, and labor dilations. Even though the studies described here were performed in persons identifying as women/female, future clinical studies with the Callascope could specifically be used with FTM transgender persons and non-binary conforming persons with cervices. This device opens new opportunities for self-monitoring in the gynecologic realm and clinician monitoring without the need of the duckbill speculum, which could address loss to follow-up, stigma, and other barriers that prevent positive health seeking behavior. The Callascope device is part of a broader paradigm shift where medical technologies can both improve clinic-based medical care and give individuals with cervices greater control and information at home.

To date, studies of self-screening for cervical cancer have primarily focused on the acceptability and feasibility of HPV self-sample collection methods, where individuals insert a brush into the vagina and rotate it to acquire samples for HPV testing. Acceptability of these studies has been measured by using scores of discomfort, pain, embarrassment, and privacy. Although physician-collected HPV samples were initially viewed as the gold standard, large-scale studies have shown that women are capable of collecting viable samples for HPV screening, and this approach is currently recommended in several resource-limited settings. HPV self-testing to screen for cervical cancer has proven successful and gives women privacy and ownership of a crucial part of the gynecological exam. We expect the same trend for self-imaging of the cervix. Even if women have access to
HPV self-testing, follow-up cervical visualization is often needed to improve screening specificity and triage HPV positive women without overburdening local health facilities, particularly in low- and middle-income countries. Self-HPV testing combined with self-visualization of the cervix using the Callascope would give women control over the entire screening process and would allow approximately 90 out of 100 women to complete care at home (only 20% of people screened have high-risk HPV57–59 and only 10% of people with high-risk HPV develop persistent infections that make them susceptible to cervical cancer60–62). In addition, our group is developing algorithms for automated colposcopy interpretation, which would augment traditional colposcopy readings by healthcare experts. Preliminary results have shown diagnostic accuracy on par with expert colposcopists46. Combining automated diagnosis following self-imaging would truly transform the paradigm of gynecologic exams.

We demonstrated the feasibility of imaging the cervix without the speculum both by clinicians and, importantly, by the patients themselves. For the clinician-imaging study, the Callascope introducer enabled visualization of the os in 78.6% of DUMC and 80% of GARH participants. Whereas, the speculum enabled visualization of the os in 96% of DUMC and 100% of GARH. Most women for whom the Callascope failed either had higher BMI, were multiparous, had given birth in the past 3 months, or had a combination of all or some of these factors. These failures occurred due to two factors: (1) the length of the Callascope introducer being insufficient to reach the cervix in women with a higher BMI, and (2) the opening of the Callascope introducer tip being insufficient to fully encompass all quadrants of the enlarged cervix within multiparous or post-natal women. In women who fall under these two categories a larger speculum was used, but this limitation could be overcome in the future by using different Callascope introducer lengths and diameters of the Calla Lily shaped opening. In other words, just as there are multiple sizes and lengths of speculums there could be Callascope devices with different viewing areas and lengths for use on patients of different BMIs, ages and parities. In order to make the cervix area visualized by the Callascope as good or better than the speculum, we will integrate improvements to the design, by exploring alternative tip sizes and lengths to account for women with higher BMIs and multiparity. For the self-imaging study most participants at DUMC (~ 60%) and GARH (~ 70%) found the Callascope easy to insert, find and image their cervixes. Only one DUMC participant reported on the survey that the Callascope was extremely hard to use. The greater ease of use indicated by participants at GARH versus DUMC may have been due to the difference in how instructions were provided. At DUMC instructions were provided using a short video tutorial and a printed user guide, after which participants were left on their own whereas at GARH instructions were given verbally by a healthcare clinician while participants used the device.

The primary aim of the paper is to demonstrate the feasibility of imaging the cervix without the speculum either by a provider, or by the patients themselves. Though the clinical studies did not include contrast application of acetic acid or Lugol's iodine to highlight suspicious lesions for screening and diagnosis, we did show on a small subset of our healthy volunteers the distribution area of contrast (Lugol's iodine) on the cervix when applied using the Callascope contrast channel. Future studies will include a randomized clinical trial, in which Lugol's iodine and acetic acid contrast agents are applied specifically to patients getting diagnosed for cervical cancer, and on whom histopathology is performed as part of the standard-of-care diagnosis procedure. This would enable us to perform an image concordance study to determine accuracy of clinician diagnosis with the Callascope versus with the standard-of-care speculum and colposcope, with pathology as ground truth. These images would also provide input for a machine learning algorithm to assess feasibility for automated risk assessment46. Other limitations include the small number of clinicians who used the device, the non-randomized nature of the study and the small sample size of patients and healthy volunteers. Future studies will seek to enroll a statistically significant clinician sample size, utilize a randomized clinical trial design and enroll a higher number of patients.

The Callascope is extremely well-suited for use in educational initiatives to improve women's awareness of their vaginal and cervical anatomy. Demystifying the cervix for women by having them see this vital organ and having them engage with their own bodies has the potential to shift the narrative around reproductive health in a positive way. When users discover their cervixes, they will likely be more comfortable talking about their reproductive health. This increased knowledge may improve their awareness of the importance of cervical cancer screening and overall sexual and reproductive health. This is expressed in representative comments participants provided about their experience with the Callascope.

We demonstrate in this manuscript the potential for a novel technology called the Callascope to address the major barriers to gynecological exams. The device has been designed to combine and replace the colposcope and speculum, providing essential information for effective visual examination of the cervix, while reducing the associated discomfort/pain. This technology replaces the speculum with a Calla Lily shaped introducer. Visual inspection with acetic acid with the naked eye (VIA) used in low and middle income settings and/or the traditional high-end colposcope (low power microscope to magnify the cervix), have been replaced with a tampon-shaped light source and camera which allows women or clinicians to capture a magnified image that is then sent to a cell phone or tablet. Furthermore, the introducer encases a working channel, which allows for contrast agent application—an important feature for cervical cancer detection. We demonstrated that the image quality of the Callascope is comparable to a high-end standard colposcope through a variety of image quality testing methods. Through studies in both the United States and Ghana, we demonstrate the effectiveness of the device for clinical use both to visualize the cervix and to perform self-exams with minimal training across a diverse population of women. Moreover, results indicate that women unequivocally prefer the Callascope over the traditional speculum.

Received: 5 April 2020; Accepted: 25 August 2020
Published online: 06 October 2020
References

1. Forcee, C. S. P. T. et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA 320, 674–688. https://doi.org/10.1001/jama.2018.10987 (2018).

2. Singh, R. H., Erbelding, E. J., Zenilman, J. M. & Ghanem, K. G. The role of speculum and bimanual examinations when evaluating attendees at a sexually transmitted diseases clinic. Sex Transm. Infect. 83, 206–210. https://doi.org/10.1136/sti.2006.023309 (2007).

3. Brown, C. L., Ludwich, M. H., Blanco, J. D. & Hirsch, C. E. Cervical dilation: Accuracy of visual and digital examinations. Obstet. Gynecol. 81, 215–216 (1993).

4. Johnson, R. & A. Insertion and removal of intrauterine devices. Am. Fam. Physician 71, 95–102 (2005).

5. Sachs, C. L., Ladd, M. & Chapman, I. In StatPearls (2020).

6. Hoye, C. et al. Pain predicts non-adherence to pap smear screening among middle-aged African American women. Prev. Med. 41, 439–445. https://doi.org/10.1016/j.ypmed.2004.11.021 (2005).

7. Khan, M., Sultana, S. S., Jabeen, N., Arain, U. & Khans, S. Visual inspection of cervix with acetic acid: A good alternative to pap smear for cervical cancer screening in resource-limited setting. J. Pak. Med. Assoc. 65, 192–195 (2015).

8. Larsen, M., Oldeide, C. C. & Malterud, K. Not so bad after all…, women’s experiences of pelvic examinations. Fam. Pract. 14, 148–152 (1997).

9. Seehusen, D. A. et al. Improving women’s experience during speculum examinations at routine gynaecological visits: Randomised clinical trial. BMJ 333, 171. https://doi.org/10.1136/bmj.38888.388519.55 (2006).

10. Beavis, A. L., Gravitt, P. E. & Rositch, A. F. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer 123, 1044–1050. https://doi.org/10.1002/cncr.30507 (2017).

11. Kahn, J. A., Goodman, E., Huang, B., Slap, G. B. & Emans, S. J. Predictors of Papanicolaou smear return in a hospital-based adolescent and young adult clinic. Obstet. Gynecol. 101, 490–499 (2003).

12. Abotchie, P. N. & Shokar, N. K. Cervical cancer screening among college students in Ghana: Knowledge and health beliefs. Int. J. Gynecol. Cancer 19, 412–416 (2010).

13. Ebu, N. I., Mupepi, S. C., Siakwa, M. P. & Sampselle, C. M. Knowledge, practice, and barriers toward cervical cancer screening in the United States. J. Pak. Med. Assoc. 65, 383–386. https://doi.org/10.1166/jpma.2016.1260–1269 (2006).

14. Weitlauf, J. C. et al. Distress and pain during pelvic examinations: Effect of sexual violence. Obstet. Gynecol. 112, 1343–1350. https://doi.org/10.1097/AOG.0b013e31818e67c8 (2008).

15. Crowley, D. L. G. In Comprehensive Gynecology Ch. 9, 2012.

16. (IARC), I. A. F. R. o. C. GLOBOCAN Cervix Uteri ASR (W) per 100,000, all ages, https://globocan.iarc.fr/old/bar sexe site.asp?selection=41628ttile=Cervix uterustastic&2populations=8window=1grid=1&color=5&color2=5&color3=2&submit=t=6%3C%3E%20Execute (2012).

17. Garcia-Moreno, C. et al. Prevalence of intimate partner violence: Findings from the WHO multi-country study on women's health and domestic violence. Lancet 368, 1260–1269. https://doi.org/10.1016/S0140-6736(06)69523-8 (2006).

18. Williams, C. M., McCloskey, L. A. & Larsen, U. Sexual violence at first intercourse against women in Moshi, northern Tanzania: Prevalence, risk factors, and consequences. Popul. Stud. 62, 335–348. https://doi.org/10.1080/00324720802315459 (2008).

19. Lyimo, F. S. & Beran, T. N. Demographic, knowledge, attitudinal, and accessibility factors associated with uptake of cervical cancer screening among women in a rural district of Tanzania: Three public policy implications. BMC Public Health 12, 22. https://doi.org/10.1186/1471-2458-12-22 (2012).

20. Reisner, S. L. et al. Comparing self- and provider-collected swabbing for HPV DNA testing in female-to-male transgender adult care in Kwazulu-Natal, South Africa: A qualitative study. BMC Infect. Dis. 12, e1–e9. https://doi.org/10.1186/1471-2458-12-22 (2012).

21. Garcia-Moreno, C. et al. Prevalence and correlates of self-perceived eating disorder symptoms among young women in a rural Indian population. Int. J. Legal Med. 133, 1261–1269. https://doi.org/10.1007/s00414-019-02271-9 (2019).

22. Potter, J. et al. Cervical cancer screening for patients on the female-to-male spectrum: A narrative review and guide for clinicians. J. Gen. Intern. Med. 30, 1857–1864. https://doi.org/10.1007/s11606-015-3462-8 (2015).

23. Ostensson, E. et al. Barriers to and facilitators of compliance with clinic-based cervical cancer screening: Population-based cohort study of women aged 23–60 years. PLoS ONE 10, e0128270. https://doi.org/10.1371/journal.pone.0128270 (2015).

24. Yoo, W. et al. The prevalence and characteristics of cervical cancer screening in rural mountainous Honduras: Knowledge, attitudes and barriers. Rural Remote Health 17, 3820. https://doi.org/10.22605/RRH3820 (2017).

25. McDonald, Y. J. et al. Health service accessibility and risk in cervical cancer prevention: COMPARING rural versus nonrural residence in New Mexico. J. Rural Health 33, 382–392. https://doi.org/10.1111/jrhh.12202 (2017).

26. Wang, C. The impact of car ownership and public transport usage on cancer screening coverage: Empirical evidence using a spatial analysis in England. J. Transp. Geogr. 56, 15–22. https://doi.org/10.1016/j.jtrangeo.2016.08.012 (2016).

27. Franco, E. L. Self-sampling for cervical cancer screening: Empowering women to lead a paradigm change in cancer control. Curr. Oncol. 25, e1–e3. https://doi.org/10.3747/coc.25.3969 (2018).

28. Mura, J. et al. Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis. PLoS ONE 12, e0183924. https://doi.org/10.1371/journal.pone.0183924 (2017).

29. Jacobson, M. In Women’s Health (2014).

30. Jayant, K., Rao, R. S., Nene, B. M. & Dale, P. S. Improved stage at diagnosis of cervical cancer with increased cancer awareness in a rural Indian population. Int. J. Cancer 63, 161–163 (1995).

31. Suarez, L., Roche, R. A., Nichols, D. & Simpson, D. M. Knowledge, behavior, and fears concerning breast and cervical cancer among older low-income Mexican-American women. Am. J. Prev. Med. 13, 137–142 (1997).
40. Sankaranarayanan, R., Badukh, A. M. & Rajkumar, R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ. 79, 954–962 (2001).

41. Patra, S., Upadhyay, M. & Chhabra, P. Awareness of cervical cancer and willingness to participate in screening program: Public health policy implications. J. Cancer Res. Ther. 13, 318–323. https://doi.org/10.4103/0973-1482.187279 (2017).

42. Eze, J. N., Umaoera, O. U., Obuna, J. A., Egwuatu, V. E. & Ejikeme, B. N. Cervical cancer awareness and cervical screening uptake at the Mater Misericordiae Hospital, Akpok, Southeast Nigeria. Ann. Afr. Med. 11, 238–243. https://doi.org/10.4103/1996-3519.102856 (2012).

43. Coronado Interis, E., Anakwenzie, C. P., Aung, M. & Jolly, P. E. Increasing cervical cancer awareness and screening in Jamaica: Effectiveness of a theory-based educational intervention. Int. J. Environ. Res. Public Health https://doi.org/10.3390/ijerph13010053 (2015).

44. Arevian, M., Noureddine, S. & Kabakhian-Khasholian, T. Raising awareness and providing free screening improves cervical cancer screening among economically disadvantaged Lebanese/Armenian women. J. Transcult. Nurs. 17, 357–364. https://doi.org/10.1177/1043659606291542 (2006).

45. Asiedu, M. N. et al. Design and preliminary analysis of a vaginal insertor for speculum-free cervical cancer screening. PLoS ONE 12, e0177782. https://doi.org/10.1371/journal.pone.0177782 (2017).

46. Asiedu, M. N. et al. Development of algorithms for automated detection of cervical pre-cancers with a low-cost, point-of-care, Pocket Colposcope. IEEE Trans. Biomed. Eng. 66, 2306–2318. https://doi.org/10.1109/TBME.2018.2887208 (2019).

47. Lam, C. T. et al. An integrated strategy for improving contrast, durability, and portability of a Pocket Colposcope for cervical cancer screening and diagnosis. PLoS ONE 13, e0192530. https://doi.org/10.1371/journal.pone.0192530 (2018).

48. Mueller, J. L. et al. Portable Pocket colposcopy performs comparably to standard-of-care clinical colposcopy using acetic acid and Lugol’s iodine as contrast mediators: An investigational study in Peru. BJOG 125, 1321–1329. https://doi.org/10.1111/1471-0528.13526 (2018).

49. Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676–682. https://doi.org/10.1038/nmeth2019 (2012).

50. Administration, F. a. D. Cleared Sterilants and High Level Disinfectants with General Claims for Processing Reusable Medical and Dental Devices. https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm (2015).

51. Rutala, W. A., Weber, D.J. & the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guideline for Disinfection and Sterilization in Healthcare Facilities. Center for disease control (2008).

52. Gupta, R., Sharma, K. & Dhiman, U. K. Effect of a combination of oral midazolam and low-dose ketamine on anxiety, pain, swelling, and comfort during and after surgical extractions of mandibular third molars. Indian J. Dent. Res. 23, 295–296. https://doi.org/10.4103/0970-9290.100460 (2012).

53. Nott, J. P., Bonnely, E. A., Pickering, J. D. & Simpson, N. A. The structure and function of the cervix during pregnancy. Transl. Res. Anat. 2, 1–7 (2016).

54. Waller, J. et al. Acceptability of unsupervised HPV self-sampling using written instructions. J. Med. Screen 13, 208–213. https://doi.org/10.1177/1400057615607828 (2006).

55. Petignat, P. et al. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol. Oncol. 105, 530–535. https://doi.org/10.1016/j.ygyno.2007.01.023 (2007).

56. Dzuba, I. G. et al. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J. Womans Health Gend. Based Med. 11, 265–275. https://doi.org/10.1089/jwh.2009.0753 (2009).

57. Paz-Zulueta, M. et al. Prevalence of high-risk HPV genotypes, categorised by their quadravalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. BMC Cancer 18, 112. https://doi.org/10.1186/s12885-018-4033-2 (2018).

58. Dunne, E. F. et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National Health And Nutrition Examination Survey, 2003–2006: Opportunity to measure HPV vaccine impact?. J. Infect. Dis. 204, 562–565. https://doi.org/10.1093/infdis/jir342 (2011).

59. Dunne, E. F. et al. Prevalence of HPV infection among females in the United States. JAMA 297, 813–819. https://doi.org/10.1001/jama.297.8.813 (2007).

60. Ho, G. Y. et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87, 1365–1371. https://doi.org/10.1093/jnci/87.18.1365 (1995).

61. Franco, E. L. et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J. Infect. Dis. 180, 1415–1423. https://doi.org/10.1086/315086 (1999).

62. Molano, M. et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study. Am. J. Epidemiol. 158, 486–494. https://doi.org/10.1093/aje/kw171 (2003).

Acknowledgements

The authors would like to acknowledge the National Institutes of Health and the Duke Global Health Institute Dissertation Fellowship for funding this work. The authors would like to thank Joseph Sarfo for his administrative efforts; Eric Stach for 3D fabrication training; Alaattin Erkanli for his contribution to the statistical analysis; Aaron Randall, and Alfredo Velasco for their technical contributions in the mobile application development, the nurses and midwives at the GARH Family Planning Unit for their invaluable efforts in support of the studies at GARH; Jennifer Gallagher, Bonnie Thiele, Kristin Weaver, and the residents and nurses at the Duke perinatal unit and obestrics and gynecology department for their invaluable efforts in support of the studies in DUMC. The authors would also like to acknowledge Brian Crouch for reviewing and editing the manuscript.

Author contributions

M.N.A. and N.R. designed and built the Callascope used for this study, and C.T.L. provided additional technical expertise. M.N.A. designed the mobile application software used in the study. M.N.A., M.S.K., J.W.S., and N.R. designed the provider-imaging clinical study conducted at Duke University Medical Center (DUMC). A.E performed statistical and power analysis, M.N.A., E.S.K., and J.W.S curated the data for the provider-imaging study at DUMC. M.N.A., J.S.A., M.S.K., M.H., and N.R. designed the self-imaging clinical study conducted at DUMC. M.N.A., J.S.A. and M.S.K. obtained regulatory approval for clinical studies conducted at DUMC. M.N.A., J.S.A. and M.E.D. curated the data for the self-imaging study at DUMC. M.N.A., M.S.K., K.A.O., A.S. and E.Sr. designed and sought regulatory approval for the provider-imaging and self-imaging clinical studies at Greater Accra Regional Hospital (GARH). M.N.A., D.A., and J.A. curated data for the provider-imaging and self-imaging study at GARH. M.N.A., J.S.A., and M.E.D. analyzed the clinical data from all sites. M.N.A., J.S.A., M.S.K., C.T.L. and N.R. acquired funding for the studies. J.W.S., M.H., E.Sr., D.A. and J.A. provided clinical resources for the
clinical studies. M.N.A., J.S.A. and N.R. wrote the original draft of the manuscript. M.N.A. generated the figures in the manuscript. All authors critically reviewed the manuscript.

**Funding**
NIH 1R01CA193380 and R01CA195500, Duke Global Health Institute Dissertation Fellowship.

**Competing interests**
MNA, MSK, and NR, have founded a company called Calla Health Foundation to commercialize the Callascope. They and other team members (JSA, ESk, CTL) have developed technologies related to this work where the investigators or Duke may benefit financially if this system is sold commercially. For the concept of this system a patent has been awarded to MNA, JSA, CTL and NR with the title: "Colposcopes and mammoscopes having curved ends and flat ends, associated methods, and speculum-free imaging methods". U.S. Patent Application No. 16/089,522. This does not alter the authors' adherence to Scientific Report's policies on sharing data and materials. Other authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to M.N.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020